Allogene Therapeutics
Melanie G. is a Scientist specializing in Flow Cytometry at Allogene Therapeutics since December 2019, focusing on product characterization and phenotyping of genetically engineered allogeneic CAR-T cells. Previously, Melanie G. served as a Senior Associate Scientist and Associate Scientist in Product Understanding and Flow Cytometry. Experience includes tutoring general biology concepts at the Student Learning Center, a summer internship at AbbVie evaluating exosomes as biomarkers, and working as a Molecular Biology Research Assistant at Kipling Will Lab, where research involved gut microbial diversity and chemical defense mechanisms in beetles. Education includes a Bachelor's degree in Molecular and Cellular Biology with a focus on Immunology and a minor in English from the University of California, Berkeley.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.